Abstract:
The present invention provides screening methods which may be regarded as in vitro or ex vivo methods of interrogating the immune system to understand what viral antigens are “seen” and responded to by T cells of the immune systems during viral infection. The screening methods further link in vitro or ex vivo responses to progression of infection in subjects.
Abstract:
A method of fabricating at least one single-crystal alloy semiconductor structure, comprising: forming at least one seed on a substrate for growth of at least one single-crystal alloy semiconductor structure, the at least one seed containing an alloying material; providing at least one structural form on the substrate which is crystallized to form the at least one single-crystal alloy semiconductor structure, the at least one structural form being formed of a host material and comprising a main body which extends from the at least one seed and a plurality of elements which are connected in spaced relation to the main body; heating the at least one structural form such that the material of the at least one structural form has a liquid state; and cooling the at least one structural form, such that the material of the at least one structural form nucleates at the least one seed and crystallizes as a single crystal to provide at least one single-crystal alloy semiconductor structure, with a growth front of the single crystal propagating in the main body of the respective structural form away from the respective seed; wherein the plurality of elements of each structural form provide reservoirs of the alloying material in liquid state, such that successive ones of the plurality of elements act to maintain, in liquid state, an available supply of the alloying material to the growth front of the single crystal in the main body of the respective structural form.
Abstract:
Through a combination of in vitro and in vivo approaches, the inventors show that human IgG2 (h2) delivers unique FcγR-independent agonistic activity to anti-CD40 antibodies and to antibodies specific to other immunostimulatory receptors, including 4-1BB and CD28. Investigation of an anti-human CD40 mAb, LOB7.4, revealed that the unique activity of h2 was dependent upon the precise arrangement of hinge and CH1 disulfide bonds. Chemical ‘shuffling’ or mutagenesis to ‘lock’ LOB7.4 into either a more flexible ‘h2A’ or more compact ‘h2B’ conformation endowed antagonistic and agonistic properties, respectively. Engineering of h2 in this way allows development of reagents with either immunostimulatory or immunosuppressive characteristics, with direct implication for the design of therapeutic mAb agents and fusion proteins.
Abstract:
First and second coherent light beams of the same wavelength are propagated in opposite directions to interact on a sub-wavelength thickness metallic metamaterial layer which is structured with a periodicity such that there is a resonance matched to the wavelength of the coherent beams. The first beam is then able to modulate the intensity of the second beam by modulating the phase and/or intensity of the first beam. The interference of the counter- propagating beams can eliminate or substantially reduce Joule loss of light energy in the metamaterial layer or, on the contrary, can lead to a near total absorption of light, depending on the mutual phase and/or intensity of the interacting beams. A modulation is thus provided without using a non-linear effect.
Abstract:
The present invention relates to Surfactant Protein D (SP-D) or nucleic acids encoding SP-D or variants thereof such as surfactant protein A or mannan binding lectin for use in the treatment and/or prevention of a parasitic infection. Methods for determining the presence of a parasitic infection by determining levels of SP-D in a sample are also disclosed. Also disclosed are helminths for treating allergy, inflammation or infection.
Abstract:
Apparatus (2) for sensing at least one parameter in water, which apparatus (2) comprises: (i) a dissolved oxygen sensor (4) for sensing dissolved oxygen in the water; and which apparatus (2) is such that: (ii) the dissolved oxygen sensor (4) has a working electrode and a reference electrode; and (iii) a voltage signal is applied between the working electrode and the reference electrode, and the voltage signal provides a conditioning waveform, then a wait time, and then a measurement function.
Abstract:
Apparatus comprising at least one optical device (106) optically coupled to at least one waveguide (111) on an optical chip (100), characterised in that: (i) the optical device (106) is optically aligned with the waveguide (111) by aligning means (114, 116); (ii) the aligning means (114, 116) comprises at least one male member (114) and at least one female (116) member which locate together; (iii) one of the male member (114) and the female member (116) is positioned on the optical chip (100); (iv) the other one of the male member (114) and the female member (116) is positioned on a capping chip (102); and (v) the apparatus includes a mirror (108) for reflecting light from the optical device (106) to the waveguide (111).
Abstract:
Protein conjugate comprising a protein antigen for generating an immune response against the HER2/neu protein and an immunogenic carrier covalently bonded to said protein antigen, wherein said protein antigen (i) has a sequence segment of 300 or more contiguous amino acids of the amino acid sequence of SEQ ID NO: 1; or (ii) has a variant sequence segment of 300 or more amino acid residues, wherein the amino acid sequence of said variant sequence segment has at least 85% sequence identity to a sequence portion from SEQ ID: 1; or (iii) has a variant sequence segment of 300 or more amino acid residues and has from 1 to 10 substitutions, deletions or additions in said variant sequence segment compared to a sequence segment of 300 or more amino acid residues of the amino acid sequence of SEQ ID NO: 1 or 2.
Abstract translation:包含用于产生针对HER2 / neu蛋白的免疫应答的蛋白质抗原的蛋白质缀合物和与所述蛋白质抗原共价结合的免疫原性载体,其中所述蛋白质抗原(i)具有氨基酸的300个或更多个连续氨基酸的序列片段 SEQ ID NO:1的序列; 或(ii)具有300个或更多个氨基酸残基的变体序列片段,其中所述变体序列片段的氨基酸序列与SEQ ID:1的序列部分具有至少85%的序列同一性; 或(iii)具有300个或更多个氨基酸残基的变体序列片段,并且与所述变体序列片段中的氨基酸序列的300个或更多个氨基酸残基的序列片段相比,具有1至10个取代,缺失或添加 SEQ ID NO:1或2。
Abstract:
A process for the electrochemical deposition of a semiconductor material, which process comprises: (i) providing a non-aqueous solvent; (ii) providing at least one precursor salt which forms a source of the constituent elements within the semiconductor material to be deposited; and (iii) electrodepositing the semiconductor material onto an electrode substrate using the precursor salt in the non-aqueous solvent, characterised in that: (iv) the semiconductor material is a p-block or a post-transition metal semiconductor material containing at least one p-block element or post-transition metal; and (v) the non-aqueous solvent is a halocarbon non-aqueous solvent.
Abstract:
Apparatus (2) for sensing at least one parameter in water, which apparatus (2) comprises: (i) a conductivity sensor (6) for sensing conductivity in water; (ii) the conductivity sensor (6) is an electrode-based conductivity sensor having bare electrodes (12) which contact the water; (iii) there are at least four of the electrodes (12); (iv) the conductivity sensor (6) is fabricated on a substrate (14) using photolithography and etching; (v) the conductivity sensor (6) is an open cell sensor having a physically unconstrained electric field; (vi) the conductivity sensor (6) is of a dot construction comprising a dot and a surrounding formation; (vii) the conductivity sensor (6) has two electrodes which are for current stimulation and which geometrically bound and enclose another two electrodes which are for voltage sensing; and (viii) the conductivity sensor (6) is a laminar construction on the substrate (14).